netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Results

Looking for Adalimumab found 40 matches

Formulary items 4 matches
   
Formulary BNF Category
  Restricted Drug  Adalimumab  (Humira®)
(Ophthalmology)
Other anti-inflammatory preparations - 11.04.02
  Adalimumab  (Humira®)
(Dermatology)
Drugs affecting the immune response - 13.05.03
  Adalimumab  (Humira®)
(Gastroenterology)
Cytokine inhibitors - 01.05.03
  Adalimumab  (Humira®)
(Rheumatology)
Cytokine modulators - 10.01.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Commissioning statement for the the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed  (10.01.03)
link in drug section Commissioning statement for the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed  (10.01.03)
link in drug section Commissioning statement for the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed  (10.01.03)
link in drug section Commissioning statement for the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed  (10.01.03)
link in drug section Commissioning statement for the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed  (10.01.03)
link in drug section Commissioning statement for the use of adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section Commissioning Statement on the use of adalimumab and dexamethasone implant for non-infective uveitis (11.04.01)
link in subsection Commissioning statement on the use of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy, NICE TA 329 (including a review of TA140 and TA262) (01.05.03)
link in drug section Commissioning statement on the use of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy, NICE TA 329 (including a review of TA140 and TA262) (01.05.03)
link in drug section Commissioning statement on the use of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy, NICE TA 329 (including a review of TA140 and TA262) (01.05.03)
link in drug section Commissioning statement on the use of infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy, NICE TA 329 (including a review of TA140 and TA262) (01.05.03)
link in drug section NICE TA 187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (01.05.03)
link in drug section NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (01.05.03)
link in drug section NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) (01.05.03)
link in drug section NICE TA 375 :Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (10.01.03)
link in drug section NICE TA146: Psoriasis - adalimumab (13.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)  (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195: adalimumab, etanercept, infliximab, rituximab and abtacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor  (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: etanercept inflximab and adalimumab for treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA383 - Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis (11.04.01)


 

netFormulary